ADC Therapeutics SA - Common Shares (ADCT)

Historical Holders from Q2 2020 to Q3 2025

Symbol
ADCT on NYSE
CUSIP
H0036K147
Type / Class
Equity / Common Shares
Shares outstanding
124M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
68.2M
Holdings value
$273M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
105
Number of buys
53
Number of sells
-26
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ADC Therapeutics SA - Common Shares (ADCT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 14% $49M 15.7M Redmile Group, LLC Jun 30, 2025
HPWH TH AG 9.61% $14.3M 9.79M Dr. Hans-Peter Wild May 15, 2025
Point72 Asset Management, L.P. 7% $10.5M 7.83M Point72 Asset Management, L.P. Jun 16, 2025
Prosight Management, LP 5.8% $28.8M 7.2M Prosight Management, LP Sep 30, 2025
BlackRock, Inc. 5% -4% $5.99M -$120K 4.91M -1.97% BlackRock, Inc. Mar 31, 2025
Oaktree Capital Group Holdings GP, LLC 4.14% $18.7M 4.67M Oaktree Fund Administration, LLC Sep 30, 2025
ORBIMED ADVISORS LLC 3.6% $4.19M 3.44M ORBIMED CAPITAL LLC Dec 31, 2024

Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 68.2M $273M -$9.53M $4.00 105
2025 Q2 68M $182M +$35.6M $2.68 84
2025 Q1 54.8M $77.3M -$2.53M $1.41 82
2024 Q4 56.5M $112M -$3.04M $1.99 81
2024 Q3 54.9M $173M +$3.39M $3.15 78
2024 Q2 51.8M $164M +$51.4M $3.16 73
2024 Q1 34.7M $156M -$1.54M $4.49 37
2023 Q4 34M $56.4M -$6.84M $1.66 35
2023 Q3 39.5M $35.4M -$10.3M $0.90 39
2023 Q2 45.4M $97.5M -$1.94M $2.15 55
2023 Q1 46.6M $90.9M +$6.16M $1.95 56
2022 Q4 38.8M $149M +$3.75M $3.84 59
2022 Q3 36.6M $176M +$9.04M $4.82 57
2022 Q2 34.5M $274M +$4.55M $7.95 52
2022 Q1 34.1M $501M +$2.95M $14.69 43
2021 Q4 33.8M $683M +$19.2M $20.20 49
2021 Q3 32.8M $891M -$45.6M $27.16 51
2021 Q2 33.5M $816M +$17.2M $24.35 56
2021 Q1 32.8M $801M +$22.7M $24.41 56
2020 Q4 31.5M $1.01B +$31.2M $32.01 49
2020 Q3 28M $919M +$217M $32.99 51
2020 Q2 21M $975M +$975M $46.81 40